Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute Inc (TOI) delivers community-focused cancer care through innovative treatment models and value-based services. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Access real-time updates on TOI's clinical trial advancements, partnership agreements, and operational milestones. Investors will find earnings reports, leadership updates, and market-moving news consolidated for efficient analysis. Media professionals can track press releases detailing TOI's expansion of outpatient services and community health initiatives.
Key content categories include quarterly financial disclosures, research collaborations, care model innovations, and regulatory developments. All materials are sourced directly from TOI's corporate communications, ensuring accuracy and timeliness.
Bookmark this page for streamlined access to TOI's evolving story in oncology care. Check regularly for updates that matter to stakeholders monitoring the intersection of healthcare innovation and value-based treatment delivery.
The Oncology Institute (TOI), a leading value-based oncology group in the U.S., is set to announce its Q1 2023 financial results on May 10, 2023, after market close. A conference call will follow at 5:00 p.m. ET, accessible via phone or webcast. Founded in 2007, TOI provides specialized cancer care to approximately 1.7 million patients through its network of over 60 clinics and more than 100 clinicians. With a focus on evidence-based treatments and clinical trials, TOI is committed to enhancing cancer care delivery. For more details, visit TOI's investor relations webpage.
The Oncology Institute (NASDAQ: TOI) reported an adjustment to its financials for Q4 and FY 2022, resulting in a $1.5 million increase in net loss for Q4 and a $1.5 million decrease in net income for the full year. In Q4, revenue rose 36.6% to $71 million, while gross profit increased 87.6% to $16 million. The company ended 2022 with $132 million in cash. Despite facing challenges, TOI exceeded revised revenue and EBITDA guidance. For 2023, the company forecasts revenue of $290-$320 million, up 15%-27%, and anticipates a net loss of $(25) to $(28) million, while projecting growth in value-based lives to 1.75-2 million.
The Oncology Institute reported a 36.6% revenue increase to $71 million for Q4 2022, with a net loss of $9.5 million, improved from a loss of $10.2 million in Q4 2021. Full-year revenue reached $252 million, up 24.4%, with a net income of $1.7 million, a significant increase from the prior year. The company ended 2022 with $132 million in cash and completed six practice acquisitions, expanding its market count from 10 to 15. They anticipate 2023 revenue guidance between $290 million and $320 million, reflecting 15% to 27% growth over 2022. Adjusted EBITDA for 2023 is projected at $(25) to $(28) million.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
